Table 3. Factors associated with glycemic control, LDL cholesterol and blood pressure.
| Glycemic control | LDL cholesterol | Blood pressure | ||||
|---|---|---|---|---|---|---|
| Crude model PR (95% IC) | Multivariable modela PR(95% IC) | Crude model PR (95% IC) | Multivariable modela PR ( 95% IC) | Crude model PR (95% IC) | Multivariable modelb PR (95% IC) | |
| Gender | ||||||
| Female | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Male | 0.95 (0.73–1.23) | 1.07 (0.84–1.36) | 1.00 (0.74–1.36) | 1.01 (0.72–1.42) | 1.06 (0.66–1.72) | 1.01 (0.62–1.64) |
| Age | ||||||
| Age < 65 years | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Age ≥ 65 years | 0.68(0.51–0.92) | 0.59(0.44–0.78) | 0.91 (0.67–1.24) | 0.98 (0.70–1.38) | 1.36 (0.86–2.15) | 1.61 (0.99–2.60) |
| Marital status | ||||||
| Without couple | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| With couple | 0.83 (0.65–1.05) | 0.74 (0.59–0.92) | 0.95 (0.71–1.28) | 1.03 (0.74–1.43) | 1.12 (0.68–1.84) | 1.32 (0.80–2.19) |
| Years of diasease | ||||||
| 1–10 years | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| ≥10 years | 1.37 (1.06–1.76) | 1.34 (1.05–1.71) | 0.94 (0.71–1.26) | 0.85 (0.62–1.17) | 0.93 (0.58–1.47) | 0.85 (0.53–1.34) |
| Treatment | ||||||
| No pharmacological treatment | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | – |
| OAD | 2.04 (0.77–5.37) | 1.75 (0.70–4.38) | 0.97 (0.56–1.68) | 0.99 (0.58–1.71) | 1.01 (0.45–2.27) | – |
| Insulin | 2.5 (0.89–7.02) | 1.70 (0.62–4.65) | 1.25 (0.65–2.39) | 1.29 (0.65–2.56) | 0.94 (0.29–3.05) | – |
| OAD plus insulin | 3.22 (1.24–8.36) | 2.57 (1.05–6.32) | 1.06 (0.59–1.88) | 1.13 (0.62–2.04) | 0.75 (0.29–1.92) | – |
| Complications | ||||||
| No complications | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | – |
| At least 1 complication | 0.98 (0.76–1.25) | 0.80 (0.62–1.03) | 1.13 (0.85–1.51) | 1.23 (0.89–1.69) | 0.80 (0.49–1.31) | – |
| IPAQ | ||||||
| HEPA active | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | – |
| Minimally active | 1.34 (1.04–1.73) | 1.63 (1.23–2.15) | 0.89 (0.60–1.33) | 0.91 (0.61–1.37) | 0.86 (0.45–1.65) | – |
| Inactive | 1.12 (0.83–1.53) | 1.31 (0.98–1.75) | 0.95 (0.66–1.36) | 0.93 (0.64–1.34) | 1.19 (0.70–2.02) | – |
| Depression | ||||||
| No | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | – |
| Yes | 1.05 (0.82–1.36) | 1.17 (0.94–1.45) | 1.00 (0.74–1.36) | 0.93 (0.67–1.27) | 1.54 (0.98–2.42) | – |
| EATDM-III | 1.00 (0.99–1.01) | 1.00 (1.00–1.02) | 1.00 (0.98–1.01) | 0.99 (0.98–1.01) | 0.98 (0.96–1.01) | 0.98 (0.96–1.00) |
Notes.
a
Adjusted model for gender, marital status, years of disease, treatment, complications, IPAQ, depression and EATDM-III.
b
Adjusted model for gender,age, marital status, years of disease and EATDM-III.
- IPAQ
- International Physical Activity Questionnaire
- OAD
- Oral antidiabetics
- EATDM-III
- Escala de adherencia al tratamiento de la diabetes mellitus tipo II